VMD VIEMED HEALTHCARE, INC.
Services-Misc Health & Allied Services, NEC · Nasdaq · SEC CIK 1729149 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.8%
TTM net income YoY14.8%
TTM EPS YoY11.8%
Revenue 3-yr CAGR22.3%
Net income 3-yr CAGR19.3%
Margins
Gross margin57.4%
Operating margin7.8%
Net margin5.0%
FCF margin6.9%
EBITDA margin12.9%
Returns
ROE11.0%
ROA7.6%
ROIC (approx.)11.8%
Asset turnover1.51x
Leverage & solvency
Liabilities / assets26.8%
Debt / equity0.03x
Current ratio1.25x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.45x
Accruals ratio-18.7%
Payout ratio—
Capex / revenue10.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $270.28M | $224.26M | $183.01M | $138.83M | $117.06M |
| Cost of revenue | $114.82M | $91.05M | $70.22M | $54.15M | $43.65M |
| Gross profit | $155.46M | $133.20M | $112.78M | $84.68M | $73.41M |
| R&D expense | $3.02M | $3.07M | $2.78M | $2.70M | $2.11M |
| SG&A expense | $121.37M | $106.20M | $87.88M | $68.16M | $54.89M |
| Operating income | $22.95M | $17.90M | $14.33M | $8.25M | $11.58M |
| Pretax income | $21.77M | $16.17M | $14.39M | $8.99M | $12.50M |
| Income tax | $6.39M | $4.76M | $4.15M | $2.77M | $3.38M |
| Net income | $14.93M | $11.27M | $10.24M | $6.22M | $9.13M |
| EBITDA | $51.56M | $43.27M | $36.19M | $23.88M | $22.89M |
| EPS (basic) | 0.38 | 0.29 | 0.27 | 0.16 | 0.23 |
| EPS (diluted) | 0.37 | 0.28 | 0.25 | 0.16 | 0.22 |
| Weighted avg. shares (diluted) | 40.82M | 40.81M | 40.38M | 39.81M | 40.68M |
| Balance sheet | |||||
| Cash & equivalents | $13.50M | $17.54M | $12.84M | $16.91M | $28.41M |
| Receivables | $25.59M | $24.91M | $18.45M | $15.38M | $12.82M |
| Inventory | $5.05M | $4.32M | $4.63M | $3.57M | $2.46M |
| Current assets | $48.49M | $52.88M | $38.37M | $39.74M | $47.31M |
| PP&E, net | $78.78M | $76.28M | $73.58M | $67.74M | $62.85M |
| Goodwill | $58.94M | $32.99M | $29.77M | $0 | — |
| Intangibles | $1.28M | $848,000 | $567,000 | $0 | — |
| Total assets | $199.15M | $177.07M | $154.90M | $117.04M | $117.96M |
| Current liabilities | $41.06M | $37.33M | $32.12M | $18.86M | $17.81M |
| Short-term debt | $1.09M | $409,000 | $1.07M | $0 | $1.48M |
| Long-term debt | $11.29M | $3.59M | $6.00M | $0 | $4.31M |
| Total debt | $12.38M | $4.00M | $7.07M | $0 | $5.79M |
| Total liabilities | $55.63M | $43.77M | $41.00M | $19.95M | $23.14M |
| Shareholders' equity | $141.54M | $131.39M | $113.89M | $97.09M | $94.82M |
| Net debt | -$1.12M | -$13.54M | -$5.76M | -$16.91M | -$22.62M |
| Shares outstanding | 38.02M | 39.13M | 38.51M | 38.05M | 39.64M |
| Cash flow statement | |||||
| Operating cash flow | $51.92M | $39.09M | $45.21M | $27.75M | $22.49M |
| Capital expenditure | $39.98M | $37.77M | $26.09M | $22.90M | $19.74M |
| Free cash flow | $11.93M | $1.32M | $19.12M | $4.85M | $2.75M |
| Investing cash flow | -$50.17M | -$30.70M | -$52.11M | -$23.98M | -$19.75M |
| Financing cash flow | -$5.79M | -$3.69M | $2.83M | -$15.27M | -$5.32M |
| Depreciation & amortization | $28.61M | $25.37M | $21.86M | $15.63M | $11.31M |
| Stock-based compensation | $9.13M | $6.29M | $5.85M | $5.20M | $5.15M |
| Share buybacks | $13.22M | $0 | $0 | $9.57M | $0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.